ストックスクリーナーアプリを入手
6.18
2.06%
-0.13
アフターアワーズ：
6.18
前日終値:
$6.31
開ける：
$6.32
24時間の取引高:
521.71K
Relative Volume:
0.87
時価総額：
$418.05M
収益：
-
当期純損益:
$-117.81M
株価収益率:
-3.2872
EPS:
-1.88
ネットキャッシュフロー:
$74.30M
1週間 パフォーマンス:
-13.81%
1か月 パフォーマンス:
-4.92%
6か月 パフォーマンス:
+40.14%
1年 パフォーマンス:
+73.60%
1日の値動き範囲:
$6.15
$6.47
1週間の範囲:
$6.15
$7.145
52週間の値動き範囲:
$3.0001
$13.60
Omeros Corporation Stock (OMER) Company Profile
名前
Omeros Corporation
セクター
電話
206-676-5000
住所
201 ELLIOTT AVENUE WEST, SEATTLE, WA
OMER を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
6.18 | 418.05M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-23 | 開始されました | D. Boral Capital | Buy |
| 2024-11-14 | 開始されました | Rodman & Renshaw | Buy |
| 2022-12-08 | ダウングレード | UBS | Buy → Neutral |
| 2022-11-08 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-06-08 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2021-10-01 | ダウングレード | Maxim Group | Buy → Hold |
| 2021-10-01 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-09-27 | 開始されました | JP Morgan | Neutral |
| 2021-02-01 | 開始されました | UBS | Buy |
| 2020-10-20 | 開始されました | BofA Securities | Buy |
| 2020-08-21 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-14 | 繰り返されました | Maxim Group | Buy |
| 2019-05-06 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-07-12 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-23 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-03-05 | ダウングレード | Needham | Buy → Hold |
| 2017-11-08 | 開始されました | H.C. Wainwright | Buy |
| 2017-05-11 | ダウングレード | Cantor Fitzgerald | Buy → Neutral |
| 2017-03-17 | 繰り返されました | Maxim Group | Buy |
| 2017-03-17 | 繰り返されました | Needham | Buy |
| 2016-11-16 | 繰り返されました | Wedbush | Outperform |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-08-10 | 繰り返されました | Maxim Group | Buy |
| 2016-06-03 | 開始されました | Cantor Fitzgerald | Buy |
| 2016-03-02 | 繰り返されました | Needham | Buy |
| 2016-02-29 | 繰り返されました | Wedbush | Outperform |
| 2015-11-11 | 繰り返されました | Needham | Buy |
| 2015-08-18 | 繰り返されました | WBB Securities | Strong Buy |
| 2015-08-10 | 開始されました | ROTH Capital | Buy |
すべてを表示
Omeros Corporation (OMER) 最新ニュース
Omeros’ (OMER) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Market Update: Omeros Corporation (OMER) Sees Negative Movement, Closing at 6.34 - DWinneX
Omeros (OMER) Stock Rating and Price Target Maintained by Analyst | OMER Stock News - GuruFocus
FDA Accepts Omeros (OMER) Resubmission for Narsoplimab Label Exp - GuruFocus
Omeros announces FDA acceptance of narsoplimab BLA resubmission - TipRanks
FDA Accepts Omeros (OMER) Resubmission for Narsoplimab Label Expansion - GuruFocus
Omeros gets FDA acceptance for narsoplimab BLA resubmission - Seeking Alpha
FDA Reviews Omeros' (OMER) Resubmission for Narsoplimab Approval - GuruFocus
FDA Reviews Omeros' (OMER) Resubmission for Narsoplimab Approval | OMER Stock News - GuruFocus
FDA reviews Omeros drug for stem cell transplant complication By Investing.com - Investing.com India
FDA reviews Omeros drug for stem cell transplant complication - Investing.com
FDA Sets September Decision Date for Narsoplimab: New Hope for Fatal Transplant Complication - Stock Titan
Barclays PLC Grows Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Invesco Ltd. Reduces Position in Omeros Co. (NASDAQ:OMER) - Defense World
JPMorgan Chase & Co. Has $317,000 Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Ratio Revelations: Omeros Corporation (OMER)’s Financial Metrics in the Spotlight - DWinneX
Omeros Corporation Inc. (OMER) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
How should investors view Omeros Corporation (OMER)? - uspostnews.com
Omeros Corporation’s Market Journey: Closing Weak at 7.91, Down -3.77 - DWinneX
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Omeros Co. (NASDAQ:OMER) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Atypical Hemolytic Uremic Syndrome Market Expected Rise, 2034 | Alexion Pharmaceuticals, Omeros Corporation, Novartis Pharmaceuticals, Hoffmann-La Roche, Chugai Pharmaceutical, Expected Drive Market - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Omeros Corporation (OMER) Stock: A Year of Decreases and Increases - investchronicle.com
Market Recap: Omeros Corporation (OMER)’s Negative Momentum, Closing at 6.97 - DWinneX
Omeros Co. (NASDAQ:OMER) Shares Acquired by Cerity Partners LLC - Defense World
Is it possible to buy Omeros Corporation(OMER) shares at a good price now? - uspostnews.com
Omeros Co. (NASDAQ:OMER) Position Increased by Alliancebernstein L.P. - Defense World
Franklin Resources Inc. Makes New Investment in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Sold by ExodusPoint Capital Management LP - The AM Reporter
Vanguard Group Inc. Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Raymond James Financial Inc. Invests $124,000 in Omeros Co. (NASDAQ:OMER) - Defense World
D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER) - Defense World
Corebridge Financial Inc. Sells 2,100 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' New Leukemia Drug Team Ignites Hope For Cancer FightOmeros (NASDAQ:OMER) - Benzinga
Omeros Announces the Omeros Oncology Clinical Steering Committee - GuruFocus
Omeros forms steering committee for leukemia treatment By Investing.com - Investing.com South Africa
Omeros announces oncology clinical steering committee to help guide proprietary Oncotox-AML clinical program - marketscreener.com
Omeros forms steering committee for leukemia treatment - Investing.com
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program - The Joplin Globe
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program | OMER Stock News - GuruFocus
Omeros (NASDAQ:OMER) Downgraded by StockNews.com to Sell - Defense World
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases - Yahoo
It makes sense and dollars to buy Omeros Corporation (OMER) stock - Sete News
(OMER) Technical Data - news.stocktradersdaily.com
FY2025 EPS Estimates for Omeros Reduced by Cantor Fitzgerald - Defense World
Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com - The AM Reporter
Omeros (NASDAQ:OMER) Earns "Buy" Rating from D. Boral Capital - MarketBeat
Omeros Co. (NASDAQ:OMER) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
4,671 Shares in Omeros Co. (NASDAQ:OMER) Acquired by Quantbot Technologies LP - Defense World
Omeros (NASDAQ:OMER) Receives “Hold” Rating from Needham & Company LLC - Defense World
Omeros Corporation (OMER) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):